Happy Hours Posters

Posters modérés affichés le Mercredi 19 Avril

15h00 – 16h30

Zone jaune

Modérateurs : Théodora ANGOULVANT (Tours), Pascal BOUSQUET (Strasbourg)

  • PM1-001 - T cells contribute to cardiac lymphatic remodeling post-MI - Mahmoud HOUSSARI (Rouen)
  • PM1-002 - Brugada syndrome after treatment with lamotrigine - Roya NILI (Paris)
  • PM1-003 - Association between endothelial dysfunction and brain BDNF levels in a rat model of arthritis - Martin PEDARD (Dijon)
  • PM1-004 - No common SNP associated to Sotalol-induced IKr inhibition - Joe-Elie SALEM (Paris)
  • PM1-005 - Vasorelaxing effect of a TrkB receptor agonist on mesenteric arteries - Perle TOTOSON (Besançon)
  • PM1-006 - Effect of estrogen on cardiac function and oxidative stress in renovascular hypertensive rats - Adili ABUDOUREHEMAN (Urumqi - Chine)
  • PM1-007 - Effect of cardiac ischemia/reperfusion in adjuvant-induced arthritis in rats - Johnny MORETTO (Besançon)
  • PM1-008 - Protective effects of Matricaria recutita decoction extract on human neutrophils ROS production, alcohol-induced haematological parameters changes and erythrocytes oxidative stress in rat - Hichem SEBAI (Béja - Tunisie)

 

Zone orange

Modérateurs : François GUEYFFIER (Lyon), Matthieu ROUSTIT (Grenoble)

  • PM1-009 - SGLT-2 inhibitors and severe ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database – Jean-Luc FAILLIE (Montpellier)
  • PM1-010 - Geographic Differences in Cardiovascular Effects of Recenlty Marketed Antidiabetic Drugs: a Sub-Group Meta-Analysis - Matthieu ROUSTIT (Grenoble)
  • PM1-011 - Protocol of GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a NETwork meta-analysis (GLUCOSE DINET protocol) - Guillaume GRENET (Lyon)
  • PM1-012 - Non-Insulin Glucose Lowering Drugs and risk of trauma: a nested case control study from French Health Insurance Database. - Mickael ARNAUD (Bordeaux)
  • PM1-013 - Insulin glargine 300 U/mL (Gla-300) provides more stable and more evenly distributed steady-state PK/PD profiles compared with insulin degludec in type 1 diabetes - Ronan ROUSSEL (Paris)
  • PM1-014 - Influence of Outdoor air pollution on pediatric asthma emergency department visits – Frantz FOISSAC (Paris)
  • PM1-015 - Quantification of therapeutic antisense oligonucleotides with liquid chromatography – high resolution mass spectrometry – Stanislas GRASSIN-DELYLE (Montigny Le Bretonneux)
  • PM1-016 - Tacrolimus intracellular concentrations in periperal mononuclear blood cells of liver transplant recipients: preliminary results - Antoine PETITCOLLIN (Rennes)

 

Zone rose

Modérateurs : Isabelle LACROIX (Toulouse), Nathalie MASSY (Rouen)

  • PM1-017 - Lactation suppression: what are the actual practices in France? - Nathalie PARET (Lyon)
  • PM1-018 - Valproic acid (DEPAKINE), a new mediatised scandal in France, a step towards more transparency - Marie BOULEAU (Lyon)
  • PM1-019 - Teratogenic risk of macrolides during the first trimester of pregnancy: a study with two complementary approaches within the EFEMERIS database – Agnès SOMMET (Toulouse)
  • PM1-020 - Self-medication during pregnancy: a survey at the maternity hospital of Nantes - Anne-Lise RUELLAN (Nantes)
  • PM1-021 - Use of digestive disorders medications by children exposed in utero to atropinic drugs - Justine BÉNÉVENT (Toulouse)
  • PM1-022 - Impact of drug exposure on voluntary termination of pregnancy request: a survey in Southwest France – Christine DAMASE-MICHEL (Toulouse)
  • PM1-023 - First data about nefopam exposure during pregnancy - Christine DAMASE-MICHEL (Toulouse)
  • PM1-024 - Selective serotonin re-uptake inhibitors (SSRIs) in utero exposure and prolonged QT interval: two cases of newborns - Julie LEBRUN (Montpellier)

 

Zone rouge

Modérateurs : Rodolphe GARRAFFO (Nice), Florian LEMAITRE (Rennes)

  • PM1-025 - Is the recommended dose of Micafungin suitable in every critically ill patient? – Franck SAINT-MARCOUX (Limoges)
  • PM1-026 - Does age have an impact on medical treatment in infective endocarditis? - Charlotte MARCHAND (Rouen)
  • PM1-027 - Plasma concentrations of amoxicillin and ceftazidime administered by continuous infusion according to the renal function - Matthieu GRÉGOIRE (Nantes)
  • PM1-028 - Consumption of antiretroviral used in HIV and associated expenditures in Europe during the last ten years: Impact of recent generic antiretroviral on cost reduction - Joseph RWAGITINYWA (Toulouse)
  • PM1-029 - CYP450 3A4 inhibition: differences according to the involved macrolide? – Agnès SOMMET (Toulouse)
  • PM1-030 - High dose of efavirenz (25 mg/kg) in children under 3 years old - Claire PRESSIAT (Paris)
  • PM1-031 - Influence of nebulized colimicyn dilution on the pharmacokinetics of colistin and colistimethate sodium in critical ill patients suffering from ventilator associated multiresistant germs pneumonia - Kevin BIHAN (Paris)
  • PM1-032 - Safety profile of pyremathamine and sulfadoxine combination - Adélaide MIGUEL (Reims)

 

Zone bleue

Modérateurs : Céline EIDEN (Montpellier), Valérie GIBAJA (Nancy)

  • PM1-033 - Prescription patterns of analgesic drugs in opioid maintained patients (TOXIDOL 4 study) – Nicolas AUTHIER (Clermont-Ferrand)
  • PM1-034 - Recreational use of dextromethorphan: data from the French Toxicovigilance and Poison Control Centers - Valérie GIBAJA (Nancy)
  • PM1-035 - Paracetamol: knowledge, use and potentiel overdosage in urban patients consulting their general practitioner – Nadine PETITPAIN (Nancy)
  • PM1-036 - Assessment of opioid analgesics addiction in patients with non-cancerous chronic pain followed at a center for pain assessment and treatment using a substance use disorders questionnaire derived from DSM-V criteria - Céline EIDEN (Montpellier)
  • PM1-037 - Prevalence and characteristics of chronic pain in opioids maintained patients in France (TOXIDOL 3 study) – Nicolas AUTHIER (Clermont-Ferrand)
  • PM1-038 - How Safe are Synthetic Cannabinoids ? - Juliana TOURNEBIZE (Nancy)
  • PM1-039 - Non-medical Use of Fentanyl Patches: Review of the Available Literature - Juliana TOURNEBIZE (Nancy)
  • PM1-040 - Factors associated with toxicity in methadone treated patients with a one year follow-up (the ANRS Methaville study) - Romain TORRENTS (Marseille)
  • PM2-015 - Involvement of addictovigilance in a program of detection of adverse drug events at an Emergency department (URGEIM) – Hélène PEYRIERE (Montpellier)

 

Zone verte

Modérateurs : Jean-Claude ALVAREZ (Paris), Gwenaëlle VEYRAC (Nantes)

  • PM1-041 - Incidence of encephalopathy and associated risk factors in two different ifosfamide formulations: a retrospective bicentric study - Chouki CHENAF (Clermont-Ferrand)
  • PM1-042 - Does the brand-name drug Ifosfamide EG® generate more encephalopathy in adults that Holoxan®? Study at the grenoble university hospital - Gwendal VIARD GAUDIN (Grenoble)
  • PM1-043 - Recurring acute sinus bradycardia in a woman treated by a low-dose cytarabine chemotherapy regimen: a case report - Cecile BASSELIN (Lyon)
  • PM1-044 - Vasculitis during chemotherapy with erlotinib: case report, review of literature and analysis in the French pharmacovigilance database - Faustine VIDIL (Paris)
  • PM1-045 - Myositis case during chemotherapy with docetaxel - Faustine VIDIL (Paris)
  • PM1-046 - Cancer immunotherapy by anti-PD-1: a therapeutic efficacy with immune adverse effects. A 10 months Follow up of Pembrolizumab after of marketing authorization in France – Antoine COQUEREL (Caen)
  • PM1-047 - Safety of anti PD1 in the treatment of melanoma: a survey in 90 patients treated in a French university hospital - Nagham KHANAFER (Lyon)
  • PM1-048 - Adverse events related to nivolumab in non-small cell lung cancer (NSCLC) : a retrospective observational study - Marion SASSIER (Caen)

 

Zone beige

Modérateurs : Bruno LAVIOLLE (Rennes), Célia LLORET-LINARES (Paris)

  • PM1-049 - Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology - Alexandre QUILLET (Poitiers)
  • PM1-050 - Survey on iatrogenic events, adverse drug reactions reporting and pharmacovigilance knowledge among general practitioners (GPs) in the Limousin region - Lucie LAVAUD (Limoges)
  • PM1-051 - Simplified pharmacovigilance reporting in primary care: one year results - Xavier HUMBERT (Caen)
  • PM1-052 - Drug safety and big clinical data: detection of drug-induced anaphylactic shocks (BREIZH project) - Marie-Noëlle OSMONT (Rennes)
  • PM1-053 - Reconciliation of adverse events databases: a critical point in clinical trial results - Mathieu LEFEBVRE (Lyon)
  • PM1-054 - HOPIPRAC, PRAC signals validation sentinel system, from a hospital data warehouse. - Layal EL ARIDI (Brest)
  • PM1-055 - VigiBIP®, the first Mobile App for PharmacoVigilance and AddictoVigilance: a balance sheet after a 2 years’ use - François MONTASTRUC (Toulouse)
  • PM1-056 - A pilot study of the Vigi4MED project: comparison of adverse drug reactions (ADRs) of duloxetine between patients' forum posts and the French pharmacovigilance database (FPVD) – Florelle BELLET (Saint-Etienne)

 

Zone violette

Modérateurs : Emmanuel OGER (Rennes), Marie-Christine PERAULT-POCHAT (Poitiers)

  • PM1-057 - Patient's falls during hospitalization: impact of newly prescribed fall risk-increasing drugs - Thomas GAILLAND (Grenoble)
  • PM1-058 - Crushing drugs in Geriatric units: impact of cleaning methods - Gwladys BOURDENET (Rouen)
  • PM1-059 - Exposure to drugs of abuse must be taken into account for evaluation of adverse drug reactions: evidence from serotonin syndrome related to opioid medicines in the WHO pharmacovigilance database Vigibaseâ - Thi Thu Ha NGUYEN (Toulouse)
  • PM1-060 - Adverse Drug Events as a cause of admission to an emergency department - Pierre PARREIN (Rouen)
  • PM1-061 - High anion gap metabolic acidosis with 5-oxoprolinuria following acetaminophen exposure : a case report - Christophe MAUCORPS (Caen)
  • PM1-062 - Risk of trauma-related hospitalisation and use of H1 antihistamines or anticholinergic drugs – Antoine PARIENTE (Bordeaux)
  • PM1-063 - Severe hyponatremia in an Emergency Department in 2015 : a retrospective observational study - Paul CLAVERIE (Limoges)
  • PM1-064 - The drugs that mostly frequently induce acute kidney injury: a case-non-case study of pharmacovigilance database - Marion PIERSON-MARCHANDISE (Amiens)

 

Posters Modérés affichés le Jeudi 20 Avril

18h00 – 19h30 

Zone jaune

Modérateurs : Eric DAILLY (Nantes), Françoise STANKE-LABESQUE (Grenoble)

  • PM2-001 - Are Prophylactic and Therapeutic Target Concentrations Different? The Case of Lopinavir/ritonavir or Lamivudine Administered to Infants for the Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding - Frantz FOISSAC (Paris)
  • PM2-002 - Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study) - Claire LAFOREST (Rennes)
  • PM2-003 - Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients – Déborah HIRT (Paris)
  • PM2-004 - Comparison of adherence to antiretroviral therapy (ART) generic versus brand ART substitutable by generics (currently available in France) by breaking or not fixed-dose combinations (FDC) in HIV-infected patients: a cohort study from the French National Healthcare Insurance Database (SNIIRAM) in Midi-Pyrénées region – Agnès SOMMET (Toulouse)
  • PM2-005 - Exposure to sofosbuvir and daclatasvir is unchanged in liver transplant patients on cyclosporine or tacrolimus based immunosuppression - Lauriane GOLDWIRT (Paris)
  • PM2-006 - Dolutegravir withdrawal and Adverse Drug Reactions: A retrospective study in Midi-Pyrénées – Haleh BAGHERI (Toulouse)
  • PM2-007 - Monitoring of adherence to calcineurin inhibitors using their longitudinal exposures in kidney transplant patients - Danko STAMENIC (Limoges)
  • PM2-008 - Relationship between exposure to calcineurin inhibitors over the first year after kidney transplantation and infections: a cohort study – Caroline MONCHAUD (Limoges)

 

Zone orange

Modérateurs : Nicolas AUTHIER (Clermont-Ferrand), Maryse LAPEYRE-MAESTRE (Toulouse)

  • PM2-009 - Patterns of use and diversion of benzodiazepines and related subtances in France : results of the OSIAP survey – Maryse LAPEYRE-MESTRE (Toulouse)
  • PM2-010 - What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review - Emilie JOUANJUS (Toulouse)
  • PM2-011 - Treatment of colchicine overdose with colchicine-specific Fab fragments: a pre-clinical study in Göttingen mini-pigs - Nicolas FABRESSE (Montigny-Le-Bretonneux)
  • PM2-012 - Pharmacists and request for drugs by minors: current situation in the Pays-de-La-Loire area - Marylène GUERLAIS (Nantes)
  • PM2-013 - Use of multiple sources and capture-recapture method to estimate the number of patients treated with baclofen for alcoholdependence in 2013 in a French region. - Marine AUFFRET (Lille)
  • PM2-014 - Sexual dysfunctions induced by off label use of baclofen for alcoholdependance induced: report of 14 cases – Marine AUFFRET (Lille)
 
  • PM2-016 - Cannabis hyperemesis: a new clinical entity ? - Nicolas WAGNER (Nantes)

 

Zone rose

Modérateurs : Youssef BENNIS (Amiens), Christian FUNCK-BRENTANO (Paris)

  • PM2-017 - Musculoskeletal adverse effects associated with rivaroxaban: Analysis from the French Pharmacovigilance database - Pascale LAINÉ-CESSAC (Angers)
  • PM2-018 - Pharmacological Prevention of Sudden Death in Adults – François GUEYFFIER (Lyon)
  • PM2-019 - Population Pharmacokinetic and Pharmacodymic model of Unfractionated Heparin during cardiac surgery - Xavier DELAVENNE (Saint-Etienne)
  • PM2-020 - Power assessment of rivaroxaban pharmacogenomics by simulation study - Clément BOIDIN (Saint-Etienne)
  • PM2-021 - Initiation of Fluindione : predictive factors of equilibration - Charlotte MARCHAND (Rouen)
  • PM2-022 - Intra-cranial haemorrhage and antithrombotics : therapeutic follow-up - Marwa KLAI (Saint-Etienne)
  • PM2-023 - Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonist – Theodora BEJAN-ANGOULVANT (Tours)
  • PM2-024 - Adverse Drug Reactions related to Direct Oral Anticoagulant : patient’s internet narratives versus pharmacovigilance database – Haleh BAGHERI (Toulouse)

 

Zone rouge

Modérateurs : Zoubir DJERADA (Reims), David TERNANT (Tours)

  • PM2-025 - New posaconazole formulation : which impact on therapeutic drug monitoring in hematological patients ? - Julia TONINI (Grenoble)
  • PM2-026 - Correlation between received and calculated dose of vancomycin in renal failure patients - Issam SALOUAGE (Tunis - Tunisie)
  • PM2-027 - Tacrolimus overexposure in kidney transplant recipients during the first post-operative week: is there an impact on kidney function? - Florian LEMAITRE (Rennes)
  • PM2-028 - Measuring tacrolimus concentration in bile from liver transplant recipient: an alternative matrix for therapeutic drug monitoring and pharmacokinetic studies? - Camille TRON (Rennes)
  • PM2-029 - Development of a population model and a bayesian estimator for Envarsus® in liver transplantation - Jean-Baptiste WOILLARD (Limoges)
  • PM2-030 - Inosine 5’-MonoPhosphate Dehydrogenase (IMPDH) phenotype in adults and children with or without azathioprine therapy - Antony CITTERIO-QUENTIN (Lyon)
  • PM2-031 - High-dose methotrexate population pharmacokinetic and pharmacogenetic analysis in pediatric patients with osteosarcoma – Naïm BOUAZZA (Paris)

 

Zone bleue

Modérateurs : Chantal BARIN LE GUELLEC (Tours), Sébastien FAURE (Angers)

  • PM2-032 - Population pharmacokinetics of infliximab and quantification of the risk of immunization towards infliximab in children with Crohn’s disease - Antoine PETITCOLLIN (Rennes)
  • PM2-033 - Eliglustat and CYP2D6 genotyping prior to initiation of therapy : Frequencies of CYP2D6 phenotype across French patients with type 1 Gaucher disease - Céline VERSTUYFT (Le Kremlin-Bicêtre)
  • PM2-034 - Detection of BRAFV600 mutation in circulating cell free DNA, a helpful tool for a better therapeutic monitoring - Baptiste LOUVEAU (Paris)
  • PM2-035 - How to diagnose early 5-azacytidine induced pneumonitis, a case report - Laurence GABRIEL (Troyes)
  • PM2-036 - High-dose methotrexate and risk factors for intoxication - Béatrice CLARIVET (Montpellier)
  • PM2-037 - Descriptive pharmacokinetic characteristics of a “real life” small cohort of BRAFV600E mutated metastatic melanoma patients treated with dabrafenib as monotherapy - Baptiste LOUVEAU (Paris)
  • PM2-038 - NSAIDs and oxycodone-induced Liver injury associated to CYP2C9 and GST mutations: a case report - Dorra AMOR (Le Kremlin Bicêtre)
  • PM2-039 - TDM of Regorafenib in patients with metastatic colorectal cancer: preliminary results – Anne HULIN (Créteil)

 

Zone verte

Modérateurs : Cyril GOUDET (Montpellier), Joëlle MICALLEF (Marseille)

  • PM2-040 - Pharmacokinetic-pharmacodynamic modeling of levodopa and metabolites in Parkinson’s disease patients - Amélie MARSOT (Marseille)
  • PM2-041 - Safety and efficacy of Dimethylfumarate in relapsing remitting multiple sclerosis: a real life regional study - Matthieu BÉREAU (Besançon)
  • PM2-042 - Phenotypic assessment of drug metabolic pathways and P-glycoprotein in patients treated with antidepressant - Celia LLORET-LINARES (Paris)
  • PM2-043 - Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: High Prevalence of Functional Abnormalities of Cytochrome P450 2D6. Preliminary data and ongoing study protocol - Susanne THÜMMLER (Nice)
  • PM2-044 - Cyamemazine (Tercian®): Exploration of extrapyramidal syndrome cases contained in the French pharmacovigilance database - Charles KHOURI (Grenoble)
  • PM2-045 - Atropinic (anticholinergic) burden in antipsychotic-treated patients: a cross-sectional study in a French PharmacoVigilance Database – François MONTASTRUC (Toulouse)
  • PM2-046 - A comparison of morphine and metabolites plasma levels following sustained release formulation of morphine administration in Roux-en-Y gastric bypass subjects versus matched nonsurgical control subjects: The OBEMO 2 study - Lorry HACHON (Paris)
  • PM2-047 - What are uronephrologic complications related to the consumption of psychoactive substances? - Michel SPADARI (Marseille)

 

Zone beige

Modérateurs : Jean-Luc FAILLIE (Montpellier), Marie-Laure LAROCHE (Limoges)

  • PM2-048 - Analysis of drug interactions involved in serious adverse effects in the French National Pharmacovigilance database: Focus on death outcomes and their avoidabilities - Mélanie MOLTENIS (Besançon)
  • PM2-049 - Adequacy of oral information given to research participants as regards the declaration of Helsinki - Adeline PARIS (Grenoble)
  • PM2-050 - Drug identification and risk of confounding look-alike medicines ; perception of patients, physicians and pharmacists - Frédéric TRANCHARD (Toulouse)
  • PM2-051 - Identifying potential drug-drug interactions in the French health insurance databases: application in multiple myeloma patients - Aurore PALMARO (Toulouse)
  • PM2-052 - Development and validity of a checklist assessing the risk of bias of randomized trials, observational studies and systematic reviews analyzing drug adverse events - Jean-Luc FAILLIE (Montpellier)
  • PM2-053 - Knowledge of drug-drug interactions by general practitioners residents: a prospective cohort study - Marie SOULIE (Paris)
  • PM2-054 - Getting vaccinated or not? : a survey on hospital staff motivations to receive influenza vaccine – Geneviève DURRIEU (Toulouse)
  • PM2-055 - Data and Safety Monitoring Board activity in establishments of Inter-Regional Group for Clinical Research and Innovation of South Western France and overseas departments: 5-years activity report - Sophie DURANTON (Poitiers)

 

Zone violette

Modérateurs : Antoine COQUEREL (Caen), Mathieu MOLIMARD (Bordeaux)

  • PM2-056 - Microparticles: Impact on the safety profile of active substances? - Romuald SOICHEZ (Besançon)
  • PM2-057 - Bilateral acute iris transillumination : a new serious ocular adverse effect of moxifloxacin - Roxane GOULAM (Paris)
  • PM2-058 - Toctino® (alitretinoin) : A French follow-up study of Pharmacovigilance – Annie-Pierre JONVILLE-BERA (Tours)
  • PM2-059 - Bisphosphonate-related osteonecrosis of the jaw: descriptive analysis from the French national pharmacovigilance database - Paul DE BOISSIEU (Reims)
  • PM2-060 - Drug-induced dental caries in VigiBase: bisphosphonate, adrenergic, immunosuppressant and hyperglycemic drugs - Emilie PATRAS DE CAMPAIGNO (Toulouse)
  • PM2-061 - Aseptic osteonecrosis after non-systemic administration of corticosteroids: french pharmacovigilance database and literature analysis - Nicolas SERANDOUR (Nantes)
  • PM2-062 - Pustulosis of the folds induced by tumor necrosis factor-α inhibitors: a new dermatologic entity? - Charlotte RAIMBAULT (Angers)
  • PM2-063 - Post-marketing surveillance of ROACTEMRA® (tocilizumab) safety: a six-year follow-up in France - Chouki CHENAF (Clermont-Ferrand)

Copyright © key4events - All rights reserved